α7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation by Preventing Mitochondrial DNA Release
- 5 Downloads
The mammalian immune system and the nervous system coevolved under the influence of cellular and environmental stress. Cellular stress is associated with changes in immunity and activation of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome, a key component of innate immunity. Here we show that α7 nicotinic acetylcholine receptor (α7 nAchR)-signaling inhibits inflammasome activation and prevents release of mitochondrial DNA, an NLRP3 ligand. Cholinergic receptor agonists or vagus nerve stimulation significantly inhibits inflammasome activation, whereas genetic deletion of α7 nAchR significantly enhances inflammasome activation. Acetylcholine accumulates in macrophage cytoplasm after adenosine triphosphate (ATP) stimulation in an α7 nAchR-independent manner. Acetylcholine significantly attenuated calcium or hydrogen oxide-induced mitochondrial damage and mitochondrial DNA release. Together, these findings reveal a novel neurotransmitter-mediated signaling pathway: acetylcholine translocates into the cytoplasm of immune cells during inflammation and inhibits NLRP3 inflammasome activation by preventing mitochondrial DNA release.
Neural circuits control multiple organ systems to fine-tune function and maintain homeostasis, which is crucial for survival of multicellular organisms. During infection or tissue injury, detection of the presence of pathogens or damaged host cells activates the immune system to initiate inflammatory responses. This step is essential for combating invading pathogens and promoting tissue repair. Failure to resolve inflammation, however, contributes to tissue damage and organ dysfunction. Nonresolving inflammation underlies the pathogenesis of acute and chronic diseases, including rheumatoid arthritis, atherosclerosis, cancer, obesity and insulin resistance (1). Previously, we identified a neural circuit, termed the “inflammatory reflex,” which regulates the function of the innate immune system (2,3). This prototypical regulatory pathway requires the vagus nerve, splenic CD4+ T cells that relay neural signals and produce acetylcholine, and α7 nAchR expressed in splenic macrophages and other cytokine-producing immune cells (4). Stimulation of the vagus nerve increases acetylcholine levels in the spleen, prevents excessive proinflammatory cytokine production during endotoxemia and experimental sepsis (4), and reduces disease severity in human rheumatoid arthritis (5). A key unsolved question is the molecular mechanism by which cholinergic neural signals regulate inflammatory responses in immune cells.
Extracellular high-mobility group box 1 (HMGB1) released by activated immune cells or damaged tissue cells is a cytokine-like mediator of inflammation during sterile and infectious injury (6). Administration of neutralizing anti-HMGB1 monoclonal antibody (mAb), or HMGB1 antagonists, significantly reduce the severity of experimental inflammatory disease, promotes bacterial clearance during Pseudomonas aeruginosa infection and prevents memory impairment in sepsis survivors (6, 7, 8, 9). The molecular mechanism of HMGB1 release by activated immune cells depends on activation of inflammasomes. These are multiprotein complexes that cleave procaspase-1 to mediate the proteolytic maturation of interleukin (IL)-1 β and IL-18, and pyroptosis, a form of proinflammatory programmed cell death (10, 11, 12, 13, 14, 15, 16). Genetic deletion of inflammasome components or pharmacological inhibition of caspase activity inhibits HMGB1 release (10, 11, 12, 13, 14, 15).
We and others have previously established that vagus nerve stimulation or cholinergic receptor agonists significantly inhibit HMGB1 release and prevent the systemic accumulation of HMGB1 during inflammation (17,18). Other findings indicate that the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome mediates HMGB1 release during endotoxemia or bacteremia (10, 11, 12) and that cytosolic oxidized mitochondrial DNA activates the NLRP3 inflammasome (19,20). Accordingly, here we postulated that cholinergic agonists inhibit NLRP3 inflammasome activation by preventing mitochondrial DNA release.
Materials and Methods
Lipopolysaccharides (LPS; Escherichia coli, 0111:B4), acetylcholine and adenosine triphosphate (ATP) were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA). Anti-mouse IL-1β (sc-1251), anti-mouse caspase-1 (sc-514) and anti-human caspase-1 (sc-622) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-HMGB1 mAb IgG2b 2G7 (noncommercial antibody) is originally from Critical Therapeutic (Boston, MA, USA), available upon request. Plasmids expressing procaspase-1, ASC, NLRP3 or α7 nAchR were purchased from Origene (Rockville, MD, USA). Mitotracker green and Mitotracker deep red were purchased from Invitrogen/Life Technologies (Carlsbad, CA, USA). Mito-chondrial isolation and purification kits were from Qiagen (Germantown, MD, USA). Choline/acetylcholine assay kits were from Abcam (Cambridge, MA, USA). Murine macrophage colony-stimulating factor (GM-CSF) and human macrophage colony-stimulating factor (M-CSF) were purchased from Peprotech (Rocky Hill, NJ, USA).
Mice and Vagus Nerve Stimulation
Mice deficient for the α7 nicotinic receptor (C57BL/6 background) and WT littermates were purchased from The Jackson Laboratory (Bar Harbor, ME, USA; B6.129S7-Chrna7tm1Bay, number 003232). Mice were housed at 25°C on a 12-h light/dark cycle and acclimatized for at least 1 wk before conducting experiments. For vagus nerve stimulation, mice were anesthetized with ketamine (100 mg/kg intraperitoneally [IP]) and xylazine (10 mg/kg IP). A midline cervical incision was made and the left cervical vagus nerve was isolated and placed on a bipolar platinum electrode (Plastics One, Roanoke, VA, USA). Electrical stimulation was delivered at 1 V, 2 ms and 5 Hz for 2.5 min by a stimulation module (STM100A) controlled by the AcqKnowledge software (Biopac Systems, Aero Camino Goleta, CA, USA). Three hours after vagus nerve stimulation, endotoxin (LPS from Escherichia coli, 0111:B4; Sigma-Aldrich) was injected (10 mg/kg IP). Mice were euthanized 2.5 h later and serum was obtained for determination of IL-1β, IL-18 and IL-6 concentration by enzyme-linked immunosorbent assay (ELISA). Vagus nerve studies were acute, nonsurvival procedures where the animal remained anesthetized the entire period. All experiments were performed under protocols approved by the Institutional Animal Care and Use Committee of the Feinstein Institute for Medical Research, North Shore-LIJ Health System.
Cell Isolation and Culture
Peritoneal mouse macrophages. Peritoneal mouse macrophages were isolated as described previously (15). Briefly, mice were injected intraperitoneally with 4% of sterile thioglycollate solution 3–5 d before macrophage isolation. Mice were euthanized with CO2 and were then injected intraperitoneally with 11.6% of sterile sucrose solution. Peritoneal lavage was collected and filtered through a cell strainer with a pore size of 40 μm. Cells were spinned down at 400g for 15 min. The cell pellets were then resuspended in macrophage culture medium (RPMI medium 1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin).
Bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells (BMDCs) were generated in vitro from bone marrow cells from 6- to 8-wk-old mice as previously described (15). Briefly, femurs and tibias were flushed with RPMI-1640 to release the bone marrow cells in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum, 100 mg/mL penicillin, 100 mg/mL streptomycin and 5 × 10−5 mol/L mercaptoethanol (20 ng/mL murine GM-CSF). On d 3, the supernatants were gently removed and replaced with the same volume of media. On d 6, the nonadherent cells were collected.
Human macrophages. Primary blood mononuclear cells were isolated by density-gradient centrifugation. Then cells were collected and cultured in RPMI 1640 medium with 10% heat-inactivated human serum. After 2 h incubation at 37°C, adherent cells were detached with 10 mmol/L ethylenedi-aminetetraacetic acid (EDTA), and then resuspended (106 cells/mL) in medium supplemented with human macrophage colony-stimulating factor (20 ng/mL) and cultured for 7 d.
Cell stimulation. The 106 peritoneal mouse macrophages or M-CSF-differentiated human macrophages plated in 12-well plates were primed with ultrapure LPS (500 ng/mL) for 4 h and then pulsed with ATP (5 mmol/L) for 30 min.
Levels of IL-1β, IL-18 and IL-6 in the culture medium or mouse serum samples were determined using quantitative ELISA kits (R&D Systems, Minneapolis, MN, USA) with reference to standard curves of purified recombinant proteins at various dilutions.
Western Blot Analysis
Proteins from cell-free supernatants were extracted by methanol/chloroform precipitation as described previously (15). Briefly, cell culture supernatants were precipitated by the addition of an equal volume of methanol and 0.25 volumes of chloroform and then were vortexed and centrifuged for 10 min at 20,000g. The upper phase was discarded and 500 μL methanol was added to the interphase. This mixture was centrifuged for 10 min at 20,000g, and the protein pellet was dried at 55°C, resuspended in Laemmli buffer and boiled for 5 min at 99°C. Cell extracts were prepared as described previously. Samples were separated by 4–20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) or 4–20% native PAGE and were transferred onto polyvinylidene fluoride membranes.
Reconstituted Inflammasome in HEK293A Cells
For the human NLRP3 inflammasome reconstitution assays, 0.2 × 106 HEK293A cells were seeded onto 24-well plates in cell culture media lacking antibiotics. Then, 24 h later, cells were transfected with plasmids expressing pro-IL-1β and inflammasome components (Origene), such as ASC, procaspase-1 and NLRP3 by using lipofectamine 2000. These modified cells were then cotransfected with either plasmids that express α7 nAchR or empty plasmids (Origene). The total amount of DNA was standardized to 600 ng per well by using a control plasmid. The transfection efficiency was monitored by using a GFP-encoding plasmid and fluorescent microscopy, and the transfection rate was observed to be around 70%. Cell lysates were harvested 24 h later and analyzed for caspase-1 cleavage by Western blot analysis. Non-transfected HEK293A cells do not express detectable procaspase-1. Caspase-1 activation was standardized by levels of procaspase-1 in cell lysates of transfected HEK293A cells.
Mouse peritoneal macrophages were primed with LPS for 3 h. And cells were stimulated with ATP (2.5 mmol/L) in the presence or absence of extracellular acetylcholine (1 mmol/L) for the indicated time. Then cells were washed two times with precooled 1× phosphate-buffered saline (PBS) to get rid of extracellular acetylcholine. Cell lysates were obtained, and total choline and acetylcholine levels were assessed by using a choline/acetylcholine assay kit (Abcam).
Flow Cytometry Analysis
Mitochondrial perturbation was assessed by flow cytometry as described previously (23,24) with some modifications. Briefly, BMDCs were primed with LPS (200 ng/mL) in 15-mL tubes for 2 h and then stained with Mitotracker green and Mitotracker deep red at 100 nmol/L for 30 min at 37°C. The nonadherent cells were collected and stimulated by ATP (1 mmol/L) for 15 min. Cells were quickly transferred on ice for fluorescence-activated cell sorter analysis.
Mitochondrial DNA Release Assay
The mtDNA levels in cytosol were measured as described previously (20). Briefly, 1 × 107 peritoneal macrophages were homogenized with a dounce homogenizer in the presence of protease inhibitor and then were subjected to centrifugation at 700g for 10 min at 4°C. Protein concentration and volume of the supernatant were normalized, followed by centrifugation at 10,000g for 30 min at 4°C for the production of a supernatant corresponding to the cytosolic fraction. DNA was isolated from 200 μL of the cytosolic fraction by using a DNeasy Blood & Tissue kit (Qiagen).
In the cell-free system, purified mitochondria were stimulated with CaCl2 or H2O2 (0.5 mmol/L) as described previously (23). Briefly, the purified mitochondria (120 mg protein per mL) were incubated with either 200 μmol/L CaCl2 or 0.5 mmol/L H2O2 in the presence or absence of different doses of acetylcholine for 15 min at room temperature and were immediately pelleted by centrifugation (10 min, 7,000g) at 4°C. DNA was isolated from 200 μL mitochondrial supernatant by using a DNeasy Blood & Tissue kit.
The levels of mtDNA encoding cytochrome c oxidase 1 were measured by quantitative real-time PCR with the same volume of the DNA solution. The following primers were used: mouse cychrome c oxidase I forward, 5′-GCCCCAGATA TAGCATTCCC-3′, and reverse, 5′-GTTCA TCCTGTTCCTGCTCC-3′.
Data are expressed as mean ± standard deviation (SD) of at least three independent experiments (n = 3-5). One-way analysis of variance and Student t test were used for comparison among all different groups. A p value <0.05 was considered statistically significant.
All supplementary materials are available online at https://doi.org/www.molmed.org .
Cholinergic Agonists Inhibit Inflammasome Activation
α7 nAchR Signaling Inhibits the NLRP3 Inflammasome Activation
To further investigate the role of α7 nAchR in NLRP3 inflammasome activation, we reconstituted the functional NLRP3 inflammasome in nonimmune HEK293A cells by transfection of these cells with plasmids that encode inflammasome components NLRP3, ASC and procaspase-1 (15). Western blot analysis reveals that expression of these inflammasome components in HEK293A cells induces cleavage of procaspase-1; this is indicative of a functional inflammasome (Figure 2C). Coexpression of α7 nAchR in these genetically modified cells significantly inhibited the cleavage of procaspase-1. Addition of a selective α7 nAchR agonist (PNU-28879) further decreased activation of caspase-1 (Figure 2C). Collectively, these findings establish that α7 nAchR signaling inhibits NLRP3 inflammasome activation.
α7 nAchR Signaling Attenuates ATP-Induced Mitochondrial Perturbation
Acetylcholine Accumulates in Cytoplasm upon ATP Stimulation
α7 nAchR Signaling Prevents Mitochondrial DNA Release
The inflammasome-dependent cytokines IL-1β, IL-18 and HMGB1 orchestrate the inflammatory responses to infection and sterile tissue injury. However, deregulated production of these cytokines drives the pathogenesis of many inheritable or acquired diseases and disorders, such as obesity, type 2 diabetes, atherosclerosis, arthritis, colitis and sepsis (30). Interestingly, cholinergic neural signals also inhibit the production of inflammasome-independent cytokines, including tumor necrosis factor (31). This study reveals a novel pathway through which cholinergic agonists may modulate target cells by activating intracellular cholinergic receptors on mitochrondria. Although emerging evidence shows that many nonneuron cells (such as monocytes, B lymphocytes and hepatocytes) contain intracellular pools of nicotinic cholinergic receptors, the biological function of these intracellular cholinergic receptors had previously been elusive (25,26).
Here we show that ATP stimulation induces rapid influx of acetylcholine into cytoplasm, where the acetylcholine can engage mitochondrial cholinergic receptors. Importantly, we and others show that these intracellular nicotinic cholinergic receptors (especially the α7 nAchR) are biologically functional. Addition of acetylcholine or other α7 nAchR agonists, such as choline, markedly inhibits Ca2+ or hydrogen oxide-induced mitochondrial DNA or cytochrome C release in isolated mitochondria from macrophages or hepatocytes, respectively. These findings suggest two antiinflammatory drug targets: mitochondrial membrane receptors and plasma membrane acetylcholine transporters that regulate mitochondrial homeostasis and inflammasome activity.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
- 5.Koopman FA, et al. (2012) Pilot study of stimulation of the cholinergic anti-inflammatory pathway with an implantable vagus nerve stimulation device in patients with rheumatoid arthritis. Arthritis Rheum. 64(10 Suppl):S195. Abstract No. 451.Google Scholar
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)